Fig. 13
From: Application of lipid nanovesicle drug delivery system in cancer immunotherapy
Reprint with permission from [126]. Copyright 2021, Wiley‐VCH GmbH
a Schematic Illustration of the Hybrid Vesicles from Bacteria Outer Membrane and Tumor Cell Membrane to Enhance Innate Immune Response for Personalized Immunotherapy. b TEM image of mTOMV. Scale bar = 50 nm. c Hydrodynamic size distribution and PDI of mT, OMV, and mTOMV. d The percentage of CD11b+NKG2D+ cells in 4T1 tumors (n = 3). e The percentage of CD80+CD86+ cells in 4T1 tumors (n = 3). f The percentage of CD3+CD8+ cells in 4T1 tumors (n = 3). g The percentage of CD80+CD86+ cells in lymph nodes (n = 3). h The percentage of CD3+CD8+ cells in lymph nodes (n = 3). i The relative tumor volume of CT26 tumors treated with control, mT, OMV, mT + OMV, and mTOMV, respectively (n = 7). Data are represented as mean ± SD. Statistical significances were calculated via one-way ANOVA, *p < 0.05, ***p < 0.001, ****p < 0.0001.